Results 1 to 10 of about 387,087 (317)

Idiosyncratic Drug-Induced Liver Injury: From Pathogenesis to Risk Reduction

open access: yesБезопасность и риск фармакотерапии, 2023
Idiosyncratic drug-induced liver injury (iDILI) is a rare and poorly predictable adverse drug reaction that may lead to death or liver transplantation in severe cases.The aim of the study was to review contemporary concepts of the immune-mediated ...
I. A. Mazerkina
doaj   +1 more source

A simple PCR-SSP method for detection of HLA-B*15:02, *15:13, and *15:21

open access: yesTürk Biyokimya Dergisi, 2023
This study aims to develop a simple polymerase chain reaction (PCR) sequence-specific primer method, which will be used to genotype HLA-B*15:02, HLA-B*15:13, and HLA-B*15:21.
Musa Nurfadhlina   +5 more
doaj   +1 more source

Distribution patterns of HLA-A*, B*, DRB1* allele groups among persons who underwent COVID-19

open access: yesМедицинская иммунология, 2021
The main histocompatibility complex — HLA system (Human Leukocyte Antigens) is among the most important genetic factors determining response of humans to infectious agents.
L. N. Bubnova   +13 more
doaj   +1 more source

L´association entre les gènes HLA II et la susceptibilité à l´asthme chez une population Constantinoise sélectionnée

open access: yesThe Pan African Medical Journal, 2020
INTRODUCTION: L´asthme est une maladie complexe causé par l´interaction de plusieurs gènes dont certains ont un effet protecteur et d´autres contribuent à l´apparition de la maladie.
Dahbia Ines Dahmani   +6 more
doaj   +1 more source

De Novo donor-specific anti-HLA antibody risk stratification in kidney transplantation using a combination of B cell and T cell molecular mismatch assessment

open access: yesFrontiers in Immunology
IntroductionThe presence of de novo donor-specific antibody (dnDSA) has detrimental effect on allograft outcomes in kidney transplantation. As humoral responses in transplantation are elicited targeting non-self-epitopes on donor HLA proteins, assessing ...
Elaine Chou-Wu   +3 more
doaj   +1 more source

Beyond HLA: an exploratory pilot study of non-HLA antibodies, HLA sensitization, and GSTT1 genotype in platelet transfusion refractoriness

open access: yesFrontiers in Immunology
ObjectivesPlatelet transfusion refractoriness (PTR) is a common and clinically challenging condition with complex underlying mechanisms. Human leukocyte antigen (HLA) alloimmunization is the principal cause of immune PTR (iPTR), whereas non-HLA ...
Jun Qi   +10 more
doaj   +1 more source

NGS identifies novel HLA-DQA1 and DPB1 associations with aplastic anemia in the Kazakhstani population

open access: yesFrontiers in Immunology
BackgroundAplastic anemia (AA) is a rare but serious blood disorder defined by autoimmune-driven destruction of bone marrow stem and progenitor cells.
Aida Turganbekova   +9 more
doaj   +1 more source

A generic RNA pulsed DC based approach for developing therapeutic intervention against nasopharyngeal carcinoma

open access: yesHuman Vaccines & Immunotherapeutics, 2017
The recurrent nasopharyngeal carcinoma of head-and-neck cancers pathology showed unique symptoms and clinical characteristics. The complexity of pathology poses challenges for developing therapeutic interventional approaches against nasopharyngeal ...
Rajeev K. Tyagi   +2 more
doaj   +1 more source

SIGNIFICANCE OF IMMUNOGENETIC PREDISPOSAL FOR CLINICAL COURSE OF MYASTHENIA

open access: yesМедицинская иммунология, 2014
. The aim of this work was to reveal novel criteria for prediction of clinical course in myasthenia, based on immunogenetic characteristics of the patients.
L. N. Bubnova   +3 more
doaj   +1 more source

Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response

open access: yesOncoImmunology, 2021
The antibody-dependent cellular cytotoxicity (ADCC) effector function of natural killer (NK) cells is one of the known mechanisms of action for rituximab-based anti-cancer immunotherapy.
Dhon Roméo Makanga   +15 more
doaj   +1 more source

Home - About - Disclaimer - Privacy